|
［1］FDA. Challenges and Opportunities Report, 2004［R/OL］. ［2018-08-11］. https://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm.
［2］Gobburu JV. Pharmacometrics 2020［J］. J Clin Pharmacol, 2010, 50(9 Suppl): 151S-157S.
［3］Wang Y, Bhattaram AV, Jadhav PR, et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006［J］. J Clin Pharmacol, 2008, 48(2): 146-156.
［4］FDA. PDUFA reauthorization performance goals and procedures fiscal years 2018 through 2022［EB/OL］.［2016-12-23］.https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm511438.pdf.
［5］Scott Gottlieb. How FDA plans to help consumers capitalize on advances in science［EB/OL］. ［2017-7-7］.https://blogs.fda.gov/fdavoice/index.php/2017/07/how-fda-plans-to-help-consumers-capitalize-on-advances-in-science/.
［6］谢海棠. FDA"创新行动计划"促进药品研发与审评, 2017［EB/OL］.［2018-08-11］, http://www.sohu.com/a/190221001_657312.
［7］Manolis E, Brogren J, Cole S, et al. Commentary on the MID3 good practices paper ［J］. CPT Pharmacometrics Syst Pharmacol, 2017, 6(7):416-417.
［8］EMA. EMA modelling and simulation working group plan［EB/OL］. ［2015-4-9］. http://www.ema. europa.eu/docs/en_GB/document_library/Work_programme/2015/04/WC500185865.pdf.
［9］CFDA. 临床试验数据管理工作技术指南［EB/OL］. ［2016-7-27］. http://www.cde.org.cn/zdyz.do?method =largePage&id=271.
［10］CFDA. 药物临床试验数据管理与统计分析的计划和报告指导原则［EB/OL］. ［2016-7-27］. http://www.cde.org.cn/zdyz.do?method=largePage&id=270.
［11］CFDA. 药物临床试验的一般考虑［EB/OL］. ［2017-1-18］. http://www.cde.org.cn/zdyz.do?method =largePage&id=263.
［12］CFDA. 肝功能损害患者的药代动力学研究技术指导原则［EB/OL］. ［2012-5-15］.http://www.cde.org.cn /zdyz.do?method=largePage&id=150.
［13］CFDA. 肾功能损害患者的药代动力学研究技术指导原则［EB/OL］. ［2012-5-15］. http://www.cde.org.cn /zdyz.do?method=largePage&id=145.
［14］CFDA. 药物相互作用研究指导原则［EB/OL］. ［2012-5-15］. http://www.cde.org.cn/zdyz.do?method= largePage&id=147.
［15］CFDA. 成人用药数据外推至儿科人群的技术指导原则［EB/OL］. ［2017-5-18］. http://www.cde.org.cn/ zdyz.do?method=largePage&id=262.
［16］CFDA. 儿科人群药代动力学研究技术指导原则［EB/OL］. ［2014-7-11］. http://www.cde.org.cn/zdyz.do? method=largePage&id=241.
［17］CFDA. 抗菌药物折点研究技术指导原则（网上征求意见稿）［EB/OL］. ［2017-8-18］. http://www. cde.org.cn/search.do?method=searchTitle.
［18］Marshall SF, Burghaus R, Cosson V, et al. Good practices in model-informed drug discovery and development: practice, application, and documentation［J］. CPT Pharmacometrics Syst Pharmacol, 2016, 5(3) :93-122.
［19］Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science［J］. Annu Rev Pharmacol Toxicol, 2011, 51:45-73.
［20］Mould DR. Model-based meta-analysis: an important tool for making quantitative decisions during drug development［J］. Clin Pharmacol Ther, 2012, 92(3):283-286.
［21］Vicini P, van der Graaf PH. Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan ［J］ ? Clin Pharmacol Ther, 2013,93(5):379-381.
［22］Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance［J］. Biochem Pharmacol, 1994, 47(9): 1469-1479.
［23］Barter ZE, Bayliss MK, Beaune PH, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver ［J］. Curr Drug Metab, 2007, 8(1): 33-45.
［24］Zou P, Yu Y, Zheng N, et al. Applications of human pharmacokinetic prediction in first-in-human dose estimation ［J］. AAPS J, 2012, 14(2): 262-281.
［25］Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses ［J］. J Pharmacokinet Biopharm,1993, 21(4): 457-478.
［26］Sheiner LB. Learning versus confirming in clinical drug development［J］. Clin Pharmacol Ther, 1997, 61(3):275-291.
［27］FDA. Guidance for industry population pharmacokinetics［EB/OL］.［1999-1］. https://www. fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072137.pdf.
［28］EMA. Guideline on reporting the results of population pharmacokinetic analyses［EB/OL］. ［2007-6-21］.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf.
［29］EMA. Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation ［EB/OL］. ［2016-7-29］. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211315.pdf.
［30］FDA. Physiologically based pharmacokinetic analyses-format and content guidance for industry［EB/OL］.［2016-12-01］.https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm531207.pdf.
［31］Byon W, Smith MK, Chan P, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance［J］. CPT Pharmacometrics Syst Pharmacol, 2013,2:e51.
［32］Jamsen KM, McLeay SC, Barras MA, et al. Reporting a population pharmacokinetic-pharmacodynamic study: A journal's perspective［J］. Clin Pharmacokinet, 2014, 53(2):111-122.
［33］Dykstra K, Mehrotra N, Tornoe CW, et al. Reporting guidelines for population pharmacokinetic analyses［J］. J Pharmacokinet Pharmacodyn, 2015, 42(3):301-314.
［34］Zhao P. Report from EMA workshop on qualification and reporting of physiologically-based pharmacokinetic (PBPK) modelling and simulation［J］. CPT Pharmacometrics Syst Pharmacol, 2017, 6(2):71-72.
［35］Ke A, Barter Z, Rowland-Yeo K, et al. Towards a best practice approach in PBPK modeling: Case example of developing a unified efavirenz model accounting for induction of CYPs 3A4 and 2B6［J］. CPT Pharmacometrics Syst Pharmacol, 2016, 5(7):367-376.
［36］Milligan PA, Brown MJ, Marchant B, et al. Model-based drug development: a rational approach to efficiently accelerate drug development［J］. Clin Pharmacol Ther, 2013, 93(6):502-514.
［37］Allerheiligen SR. Impact of modeling and simulation: myth or fact ［J］ ? Clin Pharmacol Ther, 2014, 96(4):413-415.
［38］FDA. Meeting of the pharmaceutical science and clinical pharmacology advisory committee2017 ［EB/OL］.https://www.fda.gov/advisorycommittees/committeesmeetingmaterials/drugs/advisorycommitteefor pharmaceuticalscienceandclinicalpharmacology/ucm535520.htm.
［39］EMA. 2014 Activity report of the Modelling and simulation working group ［EB/OL］. ［2015-4-9］. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/04/WC500185895.pdf.
［40］CFDA. 抗菌药物药代动力学药效动力学研究技术指导原则 ［EB/OL］. ［2017-8-4］. http://www.cde.org.cn/zdyz.do?method=largePage&id=225.
［41］FDA. Estimating the maximum safe starting dose in initial clinical. Trials for therapeutics in adult healthy volunteers ［EB/OL］. ［2005-7-6］. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078932.pdf.
［42］EMEA. Guideline on strategies to identify and mitigate risks for first in human clinical trial［EB/OL］. ［2007-7-20］.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/07/WC 500232186.pdf.
［43］Ring BJ, Chien JY, Adkison KK, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance［J］. J Pharm Sci, 2011, 100(10):4090-4110.
［44］Wajima T, Yano Y, Fukumura K, et al. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles［J］. J Pharm Sci, 2004, 93(7):1890-1900.
［45］Poulin P, Jones RD, Jones HM, et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach ［J］. J Pharm Sci, 2011, 100(10):4127-4157.
［46］Betts AM, Clark TH, Yang J, et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis［J］. J Pharmacol Exp Ther, 2010, 333(1):2-13.
［47］魏春敏, 王水强, 王涛. 创新药物首次人体试验风险评估的相关考虑［J］. 中国临床药理学杂志, 2017, 33(1): 90-94.
［48］ICH. ICH E14 Q&A (R3) ［EB/OL］. ［2015-12-10］. http://www.ich.org/fileadmin/Public_Web_Site /ICH_ Products/Guidelines/Efficacy/E14/E14_Q_As_R3__Step4.pdf.
［49］李丽, 杨进波. 基于生理的药代动力学模型在创新药临床研发中的应用进展［J］. 中国临床药理学杂志, 2017, 33(17): 1728-1732.
［50］Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development［J］. Clin Pharmacol Ther, 2007, 82(1):21-32.
［51］Bhattaram VA, Bonapace C, Chilukuri DM, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006［J］. Clin Pharmacol Ther, 2007, 81(2):213-221.
［52］王玉珠, 杨进波. 定量药理学在确定非劣效试验界值中的作用［J］. 中国临床药理学杂志, 2017, 33(23): 2515-2520.
［53］Mould DR. Models for disease progression: New approaches and uses［J］. Clin Pharmacol Ther, 2012,92(1):125-131.
［54］Mandema JW, Hermann D, Wang W, et al. Model-based development of gemcabene, a new lipid-altering agent［J］. AAPS J, 2005, 7(3):E513-522.
［55］ICH. E11(R1) Addendum: Clinical investigation of medicinal products in the pediatric population［EB/OL］.［2017-7-20］.http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11/ E11-R1EWG_Step4_Addendum_2017_0818.pdf.
［56］FDA. Product development under the animal rule ［EB/OL］. ［2015-1-15］. https://www.fda.gov /downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf.
［57］Bergman KL. The animal rule: The role of clinical pharmacology in determining an effective dose in humans［J］. Clin Pharmacol Ther,2015, 98(4): 365-368.
［58］FDA. Exposure-response relationships: Study design, data analysis, and regulatory applications［EB/OL］.［2003-4］.https://www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm072109.pdf.
［59］Lee JY, Garnett CE, Gobburu JV, et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008［J］. Clin Pharmacokinet. 2011, 50(10): 627-635.
［60］Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review［J］. Clin Pharmacol Ther, 2010, 88(2):166-182.
|